Tag «Sitravatinib (MGCD516)»

Sitravatinib

It’s only fair to share… Sitravatinib 1-N‘-[3-fluoro-4-[2-[5-[(2-methoxyethylamino)methyl]pyridin-2-yl]thieno[3,2-b]pyridin-7-yl]oxyphenyl]-1-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide 1-N’-[3-fluoro-4-[2-[5-[(2-methoxyethylamino)methyl]pyridin-2-yl]thieno[3,2-b]pyridin-7-yl]oxyphenyl]-1-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide MG-91516 1,1-Cyclopropanedicarboxamide, N-[3-fluoro-4-[[2-[5-[[(2-methoxyethyl)amino]methyl]-2-pyridinyl]thieno[3,2-b]pyridin-7-yl]oxy]phenyl]-N’-(4- fluorophenyl)- N-(3-fluoro-4-((2-(5-(((2-methoxyethyl)amino)methyl)pyridin-2-yl)thieno[3,2-b]pyridin-7-yl)oxy)phenyl)-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide シトラバチニブ; ситраватиниб , سيترافاتينيب , 司曲替尼 ,  Formula C33H29F2N5O4S Cas 1123837-84-2 Mol weight 629.6763 MG-516 Sitravatinib (MGCD516) UNII-CWG62Q1VTB CWG62Q1VTB MGCD-516 MGCD516 Antineoplastic, Receptor tyrosine kinase inhibitor Sitravatinib (MGCD516) is an experimental drug for the treatment of cancer. It is a small molecule inhibitor of multiple tyrosine kinases. Sitravatinib is being …